ACM
COGT icon

Altium Capital Management’s Cogent Biosciences COGT Stock Holding History

Altium Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-235,000
Closed -$2.29M – 73
2023
Q3 		$2.29M Hold
235,000
– – 1.19% 27
2023
Q2 		$2.78M Buy
+235,000
New +$2.7M 2.11% 21
2021
Q1 		– Sell
-432,563
Closed -$4.86M – 129
2020
Q4 		$4.86M Buy
+432,563
New +$4.75M 1.81% 14

Other funds holding COGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Altium Capital Management's COGT Position: Q4 2023 in Review

Altium Capital Management sold out of Cogent Biosciences (COGT) in Q4 2023, closing a stake of 235,000 shares — an estimated $2.29M sold.

Altium Capital Management first reported a position in COGT in Q4 2020 and held it in 3 quarters. The position peaked at $4.86M in Q4 2020. 144 funds tracked by Wall St. Rank hold COGT as of Q4 2023.

  • Altium Capital Management reported no remaining Cogent Biosciences position as of Q4 2023 after selling out during the quarter.
  • Altium Capital Management sold 235,000 Cogent Biosciences shares in Q4 2023, an estimated $2.29M.
  • Altium Capital Management first reported a position in Cogent Biosciences in Q4 2020 and held it in 3 quarters.
  • Altium Capital Management's Cogent Biosciences position peaked at $4.86M in Q4 2020.
  • 144 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2023.

Based on Altium Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.